Notícias e Atividades da Kyowa Kirin International

A Kyowa Kirin International pertence à Kirin.

Kirin é uma das ...

• Forbes Global 2000 (#1280);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Kirin é uma empresa listada sob o símbolo 2503 (JP).

Kirin tem presença direta em 3 países.

Kirin possui 6 subsidiárias incluindo Coca-Cola Beverages Northeast, Kyowa Chemical Industry e Kyowa Hakko Kirin.

Eles estão dentro:

• Bebidas29%
• Farmacêutica29%
• Outro43%

Veja o organograma con seus 25 executivos principais

Biografias mais buscadas da Kyowa Kirin International

• Julie Dehaene Puype, President
• Paula Soteropoulos, Director
• Wayne Bowler, Senior Vice President, Business Development & Allian...

Recentes movimentos de executivos em Kyowa Kirin International

• Richard Johnson, Senior Vice President of Head of Strategy and Human Resources, deixou a Companhia  (Notícia publicada em 5 de maio de 2026).

Criar um alerta
para seguir os movimentos de executivos da Kyowa Kirin International.

Kirin possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).

Popular M&A news in Farmacêutica

• Corden Pharma has announced the acquisition of AmbioPharm  (publicado em 5 de junho de 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (publicado em 4 de junho de 2026).
• Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board da Abbott
• Jonathan Leff - Director da Larimar Therapeutics

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Kyowa Kirin International

• Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML - Kyowa Kirin
• Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials - Kyowa Kirin
• Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis - Kyowa Kirin
• Kyowa Kirin Highlights Positive Phase 3 Topline Data from BridgeBio’s Global PROPEL 3 Study of Infigratinib in Achondroplasia - Kyowa Kirin
• Kyowa Kirin Announces Changes in Directors and Management Structure - Kyowa Kirin
• Orchard Therapeutics Celebrates Addition of Metachromatic Leukodystrophy to the U.S. Recommended Uniform Screening Panel | Orchard Therapeutics
• Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025 | Orchard Therapeutics
• Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024
• Orchard Therapeutics Celebrates Global Progress toward Advancing Newborn Screening for MLD on International Neonatal Screening Day | Orchard Therapeutics
• CTCL Global Care Collaborative Pioneers Consensus for Improving Diagnosis and Care in Cutaneous T-Cell Lymphoma (CTCL)
• View more press releases Close

Redes sociais sobre Kyowa Kirin International

• Kyowa Kirin International na Wikipedia, Google News e Yahoo Finance
• Kyowa Kirin International na LinkedIn, X (Twitter) e YouTube